Synaptogenix announces $12.5 million private placement

New york, june 14, 2021 /prnewswire/ -- synaptogenix, inc. (nasdaq: snpx), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that it has executed securities purchase agreements to raise gross proceeds of approximately $12.5 million in a private placement financing of common stock and warrants ("units"). the financing was led primarily by existing institutional shareholders.
SNPX Ratings Summary
SNPX Quant Ranking